Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Limited Resections for Very Small NSCLC Tumors and BAC
Author
Howard (Jack) West, MD

While lobectomy or pneumonectomy may be the surgical treatment of choice for most NSCLC tumors in younger, fit patients, a limited resection may be an ideal choice in certain settings. In my previous post I discussed the data supporting a limited resection in older patients, who are likely to have competing health risks that may make it less critical to pursue the most aggressive surgical strategy. Another situation in which a sub-lobar resection may be particularly appealing is when the tumor is quite small and/or has characteristics suggestive of an indolent natural history. In such cases, a lobectomy may be more surgery than is required. There are trials now asking the question of whether patients with the most favorable features based on size or histology (microscopic characteristics) may do as well or better with limited resections than the standard lobectomy or pneumonectomy.

One of the first issues is in identifying the right population for which special management should be considered. Stage IA is defined as a tumor less than 3 cm that does not involve the pleura (the lining around the lung) and is not too close to important structures in the middle of the chest, and this is the stage with the best prognosis after treatment of NSCLC. However, even within that group, several recent studies have shown that survival is particularly favorable for patients with tumors that are 2 cm or smaller. For example, Gajra and colleagues from Syracuse (abstract here) found that among their 246 consecutive patients with stage IA NSCLC tumors, survival was significantly better for those with tumors of 1.5 cm or less vs. those with larger tumors of 1.6 - 3.0 cm (5 year overall survival 85.5% vs. 78.6%, respectively). Very similar results were demonstrated in a series from NYC by Port and colleagues (abstract here), who analyzed results from 244 patients with stage IA NSCLC and found that the 5-year overall survival was 77% for those with tumors 2 cm or less, compared with 60% for those with larger tumors from 2.1 to 3.0 cm. Additional work from the group in NYC (abstract here) also showed that patients with tumors 2 cm or smaller had involvement of hilar lymph nodes half as often as the patients with larger stage IA tumors.

One study from more than a decade ago, by Warren and colleagues (abstract here), showed that the five-year survival of patients with tumors 2 cm or less were not significantly different if they underwent a segmentectomy compared to a lobectomy. However, it has been primarily more recently work that has established some momentum for sublobar resections in smaller tumors, especially work out of Japan, where the focus has been on small tumors with bronchioloalveolar carcinoma (BAC) histology.

Bronchioloalveolar carcinoma (BAC) tumors have been particularly identified as potentially demonstrating an indolent natural history and favorable survival, as I indicated in a previous post. In a retrospective review from Massachusetts General Hospital, the investigators compared survival among 33 patients with stage I BAC tumors to the survival of 105 other patients with stage I non-BAC adenocarcinomas (abstract here). They reported that the 5-year survival was 20% higher in the BAC patients:

Breathnach stage I BAC vs other adenoca (click to enlarge)

Much of the leading work on sublobar resections in BAC has emerged out of Japan, where BAC is especially common. Such studies have demonstrated that peripheral (toward the outer edges of the lung) adenocarcinomas less than 2 cm have relatively low rates of lymph node involvement, especially BAC (abstract here). Several recent small prospective trials out of Japan (abstracts here and here) have performed limited resection on small BAC tumors and seen no evidence of recurrences and 100% survival in the first 2-3 years of follow-up. Other, larger trials directly comparing sub-lobar resection to lobectomy are currently being conducted in Japan.

In the US, the Cancer and Leukemia Group B (CALGB) is running a propsective phase III trial randomizing patients with small (2 cm or less in diameter), peripheral NSCLC tumors to lobectomy vs. wedge resection or segmentectomy. Patients will undergo a mediastinoscopy to confirm no evidence of involvement of any accessible lymph nodes and will then be randomized intra-operatively to one type of surgery or the other (so before going to the operating room, people will need to know they could receive either type of surgery). Other cancer cooperative groups are joining this important trial, so it will be running throughout North America, and it will plan to accrue up to nearly 1300 patients, looking for significant differences in the rate of NSCLC recurrence by the type of surgery performed. The trial, led by Dr. Nasser Altorki from NYU, is known by the rather un-catchy name "CALGB 140503" and should become widely available soon.

Until then, the more extensive lobectomy or pneumonectomy surgeries remain the standard of care, but the study from CALGB and work emerging from Japan may lead us to refine that position.

Next Previous link

Previous PostNext Post

Related Content

Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!
Image
Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón
Video
¡El vídeo completo bajo demanda está disponible para verlo!

Forum Discussions

Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...

Hi Bluebird,  Welcome to GRACE.  I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had. 

 

A CT would be...

Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...

Hi and welcome to GRACE.  I'm sorry to know you are entering a new stage.  I'm not about to comment just now but wanted to let you know I see your...

Edit to say, we can't give advice but we can comment with views and facts.  :)

 

My first thought is to ask if she has been seen at a large...

Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...

Recent Comments

JOIN THE CONVERSATION
Tagrix FDA Approval
By mariachristian on
Hi Judy! It is so good to…
By JanineT GRACE … on
Tagrix vs Tagrisso
By Dipakchavan on
Hello Linda, my name is…
By AlexandraGBeneke on